Coherus plans Humira biosimilar sale at 85% discount

14 Jul 2023
www.pharmaceutical-technology.com
BiosimilarLicense out/in
Coherus plans Humira biosimilar sale at 85% discount
Preview
Source: Pharmaceutical Technology
Phalguni Deswal
Coherus plans Humira biosimilar sale at 85% discount
Preview
Source: Pharmaceutical Technology
Humira was AbbVie’s blockbuster drug with sales of $21.2bn in 2022. Credit: Coherus BioSciences.
Coherus BioSciences has signed a US national distribution agreement with speciality pharmacy Superior Biologics to sell the former’s Humira biosimilar at $995 per carton of two 40mg autoinjectors.
This cost is at a sharp discount from two AbbVie’s originator biologic Humira 40mg syringes, which cost $6,922.
In June 2023, Coherus explored a partnership with billionaire Mark Cuban’s online pharmacy Cost Plus Drugs, with a slightly higher price of $1,138 for two 40mg Yusimry autoinjectors. The deal did not cover additional charges for shipping and dispensing, and health insurance providers not providing coverage for the prescription.
Humira is a tumour necrosis factor (TNF) blocker that is indicated for various adult and paediatric conditions, including various forms of arthritis, Crohn’s disease, and ulcerative colitis. The therapy was AbbVie’s blockbuster drug with sales of $21.2bn in 2022.
GlobalData estimates the market for Humira biosimilars to reach is expected to reach $514.4m in 2023 across the seven major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, and Japan). Amgen’s Amjevita, Humira biosimilar, was the first to capitalise on this having started its US roll-out in January this year.
Still, the Humira biosimilars are expected to face market resistance in the US due to how certain insurers cover drug contracts, and the reluctance of both doctors and patients to switch to the biosimilar in some conditions. In 2025, GlobalData forecasts AbbVie to remain a market leader, and Yusimry to have global sales of $436m in 2025.
GlobalData is the parent company of Pharmaceutical Technology.
Coherus CEO Denny Lanfear said: “Coherus is pleased to work with Superior Biologics for nationwide distribution of Yusimry, providing patients and their plan sponsors access to a high-quality, safe, and effective treatment at significant savings compared to Humira.
“Through this unique distribution partnership, we can bring Yusmiry immediately to patients throughout the United States.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.